Axcer 90mg Tablet

Axcer 90mg Tablet

Axcer 90mg Tablet is a high-potency cardiovascular intervention containing Ticagrelor (90mg), a selective and reversibly binding P2Y12 receptor antagonist specifically engineered for the clinical management of acute coronary syndrome (ACS) and patients undergoing percutaneous coronary intervention (PCI). Utilizing a unique “Direct-Acting” antiplatelet system, this medication works by preventing ADP-mediated P2Y12 dependent platelet activation and aggregation. Unlike thienopyridines, Axcer does not require hepatic metabolic activation to exert its therapeutic effect. By maintaining a highly consistent level of platelet inhibition, it effectively reduces the rate of stent thrombosis and myocardial infarction. This targeted biochemical action provides a decisive therapeutic response by mitigating the risk of cardiovascular death and systemic embolic events in high-risk cardiac patients.

Key Features

• Specifically formulated to bypass hepatic activation, ensuring a rapid and predictable antiplatelet response.
• Clinically recognized for reducing the risk of cardiovascular death and myocardial infarction more effectively than standard therapies.
• Specifically engineered to allow for a faster return to baseline platelet function after discontinuation, aiding in surgical planning.
• Acts as a functional barrier against the formation of clots within coronary stents following angioplasty.
• Formulated to provide consistent therapeutic concentrations even in patients with genetic variations in liver enzymes.

Key Ingredients

• Ticagrelor (90mg)
• Mannitol
• Dibasic Calcium Phosphate
• Sodium Starch Glycolate
• Hypromellose (Film Coating)

Precautions

• Must be used under the strict supervision of a cardiologist; do not discontinue usage abruptly as this significantly increases the risk of a heart attack.
• Use with extreme caution in patients with active pathological bleeding, a history of intracranial hemorrhage, or severe hepatic impairment.
• Typically prescribed alongside a low maintenance dose of Aspirin (75mg–100mg); higher doses of Aspirin may decrease the clinical efficacy of Ticagrelor.
• Some patients may experience a transient sensation of shortness of breath (dyspnea); consult your physician if this becomes persistent or severe.
• Inform your doctor if you are taking strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), as these can drastically alter blood levels.
• If elective surgery is required, inform the surgeon; Axcer usually needs to be discontinued 5 days prior to the procedure to minimize bleeding.

How to Use

• Swallow the tablet whole with a glass of water. It may be taken with or without food.
• For optimal clinical results, take Axcer 90mg twice daily (morning and evening) at approximately the same time each day.
• If you have difficulty swallowing, the tablet can be crushed, mixed with water, and consumed immediately.
• Adhere to a strict daily regimen. Missed doses increase the risk of thrombotic events; take the missed dose as soon as remembered unless it is nearly time for the next.
• Regular blood tests may be required to monitor uric acid levels, as Ticagrelor can occasionally cause asymptomatic elevations.
• Keep the tablets in their original blister pack, stored in a cool, dry place (below 30°C) away from direct sunlight and humidity.

Legal Disclaimer: Axcer 90mg Tablet is a prescription-only cardiovascular medication. Individual results vary based on the clinical severity of the coronary syndrome and the patient’s overall health profile. This product is not intended for the treatment of active, uncontrollable hemorrhage. This information is for educational purposes and is not a substitute for professional medical consultation or a personalized cardiology treatment plan.